According to the Clarivate data service, the journal has an impact factor of 16.6 (2022)
What are the side effects of tirzepatide vs semaglutide
Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected with new entrants (Boehringer Ingelheim, Amgen, Pfizer, Roche amongst others) offering novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly).
M., Kalinina, S., Rueck, A., von Arnim, C
Future meta-analyses should report excluded studies with justifications, incorporate comprehensive grey-literature and expert searches, preregister protocols, and explicitly propagate primary-study risk of bias into quantitative synthesis to strengthen the reliability and generalisability of conclusions